Zimmer Biomet (ZBH) Q4 2024 Earnings Transcript

Zimmer Biomet reported Q4 revenue of $2.023 billion, up 4.3% reported and 4.9% in constant currency, with adjusted EPS of $2.31 (+5%) and adjusted operating margin expanding 50 bps to 30.8%. Management guided 2025 constant-currency revenue growth of 3%-5% and adjusted EPS of $8.15-$8.35, while flagging a 150-200 bps FX headwind and a $0.20-$0.25 EPS drag. The company also announced the $1.1 billion Paragon 28 acquisition, expected to close in 1H25 and be ~3% EPS dilutive in 2025 before turning accretive within 24 months.

Analysis

ZBH’s setup is less about a clean quarter than a credible transition from “recovery” to “self-funded reinvestment.” The market is likely underestimating how much operating leverage can reassert itself once the ERP drag, inventory normalization, and launch-related spending stop colliding at the same time; that creates a meaningful second-half inflection even if reported growth looks mediocre in the first half. The bigger strategic takeaway is that the business mix is shifting toward faster-growth, higher-touch channels where service intensity matters more than pure price, which should make revenue stickier and reduce the odds that pricing pressure meaningfully inflects negative.

The Paragon 28 deal is the real catalyst, but not just because it adds growth. It gives ZBH a foothold in a category with stronger procedural growth and higher ASC relevance, and—more importantly—it gives the company a cross-sell wedge into accounts where it already has orthopedic relationships but was previously underrepresented in foot/ankle. That matters because the synergies are likely to show up first in contracting and case capture, with EPS accretion lagging; the stock may initially trade on the larger revenue mix and market share story rather than near-term dilution, which is bullish if management executes cleanly.

The main risk is that investors focus too much on the guided FX and first-half margin pressure and miss the fact that those headwinds are largely timing, not structural. The contrarian issue is that ZBH may be setting up a re-rating if the new product cycle lands on schedule, because the street is still treating it like a low-growth mature medtech with episodic execution issues rather than a business with improving end-market participation and a widening channel footprint. The failure mode is simple: if second-half launches slip, or if integration complexity from Paragon consumes attention, the multiple can compress back toward no-growth medtech despite the stronger strategic narrative.

Key Decisions for Investors

• Go long ZBH on weakness into the first-half margin noise; preferred entry is after any post-earnings de-risking, targeting a 6-9 month horizon into the second-half launch ramp.
• Pair trade: long ZBH / short a slower-growth large-cap medtech peer with less ASC exposure (e.g., SYK on valuation relative terms) to isolate the re-acceleration and mix-upgrade story over 2-4 quarters.
• Sell downside protection on ZBH via cash-secured puts or put spreads around the next 1-2 earnings prints if implied vol stays elevated; the thesis is that guidance pessimism is already embedded while second-half upside is not.
• For event-driven exposure, buy a modest ZBH position ahead of Paragon close but hedge with a sector ETF short if you want to neutralize broad healthcare multiple risk; the key catalyst is integration clarity plus updated post-close guidance.
• Avoid chasing after a strong open; wait for the market to reprice the guided FX drag and first-quarter margin compression, then accumulate ahead of Q2/Q3 when the launch cadence should become visible.